DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus

Trial Profile

DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Lumbricus rubellus (Primary)
  • Indications Blood coagulation disorders; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Sponsors Dexa Medica
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Aug 2016 Status changed from recruiting to completed.
    • 25 Nov 2015 Planned End Date changed from 1 Aug 2014 to 1 Oct 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top